| abstract |
The present invention is (i) a compound capable of disrupting or hindering the dirin-1/dirin-1 receptor interaction or the kinetin-1 mediated receptor dimerization, also referred to herein as, in the treatment of cancer. A NTN1 neutralizer, the compound can be an antibody that binds to naturin-1 or an anti-condulin-1 antibody, and (ii) an immune checkpoint inhibitor in combination or in combination. The composition may comprise an anticonductin-1 antibody and an immune checkpoint inhibitor for use as an anticancer drug administered to a patient simultaneously, separately or sequentially with the anticonductin-1 antibody and the immune checkpoint inhibitor. |